The c-Jun N-terminal kinase (JNK) pathway is known to be activated under diabetic conditions and to possibly be involved in the progression of insulin resistance. In this study, we examined the effects of modulation of the JNK pathway in liver on insulin resistance and glucose tolerance. Overexpression of dominant-negative type JNK in the liver of obese diabetic mice dramatically improved insulin resistance and markedly decreased blood glucose levels. Conversely, expression of wild type JNK in the liver of normal mice decreased insulin sensitivity. The phosphorylation state of crucial molecules for insulin signaling were altered upon modification of the JNK pathway. Furthermore, suppression of the JNK pathway resulted in a dramatic decrease in the expression levels of the key gluconeogenic enzymes, and endogenous hepatic glucose production was also greatly reduced. Similar effects were observed in high fat, high sucrose diet-induced diabetic mice. Taken together, these findings suggest that suppression of the JNK pathway in liver exerts greatly beneficial effects on insulin resistance status and glucose tolerance in both genetic and dietary models of diabetes.
INTRODUCTION
The hallmark of type 2 diabetes is insulin resistance and pancreatic -cell dysfunction (1, 2) . Normal -cells can compensate for insulin resistance by increasing insulin secretion, but insufficient compensation leads to the onset of glucose intolerance. Once hyperglycemia becomes apparent, insulin sensitivity is further reduced and -cell function progressively deteriorates (3) . Various studies have demonstrated that hyperglycemia is the direct cause of these phenomena, collectively called "glucose toxicity" (4) (5) (6) (7) (8) .
It has been reported that the activity of c-Jun N-terminal kinase (JNK) (9) (10) (11) (12) (13) , which is known to be activated by various stress signals such as cytokines or oxidative stress, is abnormally elevated in various tissues under diabetic conditions (14) (15) (16) and that activation of the JNK pathway interferes with insulin action (14, 17) . Indeed, it was shown that insulin resistance is substantially decreased in mice homozygous for a targeted mutation in the JNK gene (14) . Furthermore, we recently reported that JNK activation is involved in the reduction of insulin gene expression by oxidative stress and that suppression of the JNK pathway can protect -cells from glucose toxicity (18) . Thus, it is likely that JNK is a crucial mediator of the progression of insulin resistance as well as -cell dysfunction found in type 2 diabetes.
Here we report that suppression of the JNK pathway in the liver improves insulin resistance in the whole body and markedly ameliorates glucose intolerance in diabetic mice.
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Glucose tolerance tests.
After a 6-h fast, mice were injected intraperitoneally with glucose (2.0 g/kg body weight). Blood samples were taken at various time points (0-120 min), and blood glucose levels and serum insulin levels were determined as described above.
Insulin tolerance tests.
After a 6-h fast, mice were injected intraperitoneally with insulin (2.0 U/kg for C57BL-KsJ-db/db mice). Blood samples were taken at various time points (0-90 min) and blood glucose levels were measured as described above.
Euglycemic hyperinsulinemic clamp.
Fourteen days before the clamp study, Ad-WT-JNK (1X10 10 PFU/ml) or Ad-DN-JNK (2×10 9 PFU/ml) was injected from the left jugular vein. Three days before the clamp study, a silicon catheter (Phicon Tube, Fuji-Systems, Tokyo, Japan) was inserted into the right jugular vein under general anesthesia with sodium pentobarbital. The catheter, which is required for infusion in the clamp study, was exteriorized at the back of the neck through a subcutaneous tunnel and filled with heparinized saline (200 U/ml). Clamp studies were performed on mice under conscious and unstressed conditions after a 6-h fast. A euglycemic hyperinsulinemic clamp with a tracer dilution method was applied to determine peripheral glucose uptake and endogenous glucose production. Experiments consisted of a 120-min euglycemic hyperinsulinemic clamp period (15 pmol/kg/min of regular human insulin for C57BL6 mice; 27 pmol/kg/min for C57BL/KsJ-db/db mice during the 120 min clamp period). During this period, blood glucose levels were monitored every 5 min and the rate of 50% glucose containing 10% [6, 66 Measurement of endogenous hepatic glucose (HGP) production by stable isotope-labeled glucose enrichment.
To estimate HGP, stable isotope-labeled glucose enrichment was determined. Blood samples were taken at 90, 105, 120 min and 20 l of each plasma sample were deproteinized with 60 l of 99.5%
ethanol. The supernatant was evaporated, and the residue was derivatized by the following procedure.
First, 7.5 l of MBTFA (N-methyl-bis (trifluoroacetamide), Pierce, Rockford, IL) and 7.5 l of pyridine were added to the residue, and the mixture was heated for 1 h at 60 C. The reaction product 
Western blot analysis.
Whole cell extracts obtained from liver were fractionated by 10% SDS-PAGE and transferred to Northern blot analysis.
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Ten micrograms of total RNA isolated from freeze-clamped liver tissues were electrophoresed on 1.0% formaldehyde-denatured agarose gel in 1 X MOPS running buffer, and then transferred overnight to a Hybond-N + membrane (Amersham, Arlington Heights, IL, USA). The PEPCK, G6Pase, and GK cDNA probes were labeled with -32 P] dCTP using the Rediprime labeling system kit (Amersham). After overnight hybridization with a 32 P-labeled probe at 42 C, the membranes were washed in 2 X SSPE, 0.1% SDS at 42 C. The probed membranes were exposed to an imaging plate, BAS-MS 2040 (Fujifilm, Tokyo, Japan), and the hybridization intensity was quantified using a BAS2500 system (Fujifilm).
Diet study.
Six-week male mice (C57BL6) were divided at random into 2 groups. One group was fed a high-fat, high-sucrose diet (AIN93G, Oriental Yeast, Suita, Japan) and the other was fed standard laboratory mouse chow (Clea Japan, Tokyo, Japan) for 4 weeks.
Statistical analysis.
Results are expressed as mean ± S.E. Differences between groups were examined for statistical significance using the Student's t test or analysis of variance (ANOVA) with the Fisher's PLSD test.
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RESULTS
Activation of the JNK pathway in the liver decreases insulin sensitivity in C57BL/6 mice.
To examine the effects of JNK overexpression in the liver on insulin sensitivity and glucose tolerance in non-diabetic animals, we prepared WT-JNK expressing adenovirus ( Ad-GFP-treated mice (18.2 ± 3.1 versus 6.4 ± 3.3 mol/kg/min, p<0.05, n = 6). In contrast, there was no difference in glucose disappearance rate between the two groups, which reflects glucose utilization in the peripheral tissues (data not shown). These results indicate that overexpression of JNK decreases insulin sensitivity mainly by increasing HGP in control mice. On the other hand, although JNK is well known to be involved in the immune response and regulation of apoptosis, HE staining revealed no morphological changes in the liver after WT-JNK overexpression (data not shown), indicating that the increase in insulin resistance induced by WT-JNK overexpression is not due to the induction of apoptosis in the liver.
Suppression of the JNK pathway in the liver markedly reduces insulin resistance and
ameliorates glucose tolerance in C57BL/KsJ-db/db mice.
To examine the effect of suppression of the JNK pathway in the liver on insulin resistance and glucose intolerance in diabetic animals, we prepared DN-JNK expressing adenovirus (Ad-DN-JNK) and control adenovirus (Ad-GFP), and delivered each adenovirus via the cervical vein to 8 week-old C57BL/KsJ-db/db obese diabetic mice. There was no difference in body weight and food intake between the two groups (data not shown). As shown in Fig. 2A , when C57BL/KsJ-db/db mice were treated with Ad-DN-JNK, nonfasting blood glucose levels were markedly reduced from 405 ± 42 mg/dl to 211 ± 30 mg/dl (2 weeks after adenovirus injection), whereas no such effect was observed in
Ad-GFP-treated mice. Fasting blood glucose concentrations (after a 6-h fast) were also lower in
Ad-DN-JNK-treated mice compared to Ad-GFP-treated mice, although there was no difference in serum insulin concentrations between these two groups (Fig. 2B) . To examine the effect of suppression of JNK activity in the liver on insulin resistance, we performed intraperitoneal insulin tolerance test (IPITT). As shown in Fig. 2C , the hypoglycemic response to insulin was larger in
Ad-DN-JNK-treated C57BL/KsJ-db/db mice compared to Ad-GFP-treated mice. To investigate this point further, we performed the euglycemic hyperinsulinemic clamp test. As shown in Fig. 2D , in the 10 clamp study, GIR in Ad-DN-JNK-treated mice was around 2-fold higher than that in Ad-GFP-treated mice (20.8 ± 2.4 versus 10.1 ± 2.6 mg/kg/min, p<0.05, n = 6), indicating that suppression of the JNK pathway in the liver reduces insulin resistance and thus ameliorates glucose tolerance in C57BL/KsJ-db/db mice. Furthermore, hepatic glucose production was significantly lower in
Ad-DN-JNK-treated mice compared to Ad-GFP-treated mice (24.0 ± 4.2 versus 38.0 ± 3.9 mol/kg/min, p<0.05, n = 6) (Fig. 2D ). In contrast, there was no difference in the glucose disappearance rate between these two groups (data not shown). These results indicate that reduction of insulin resistance and amelioration of glucose tolerance by DN-JNK overexpression are mainly due to suppression of hepatic glucose production.
Next, we examined whether Ad-DN-JNK exerts some effect on glucose tolerance and insulin sensitivity in non-diabetic C57BL6 mice. In contrast to C57BLKsJ-db/db mice, there was no difference in fasting blood glucose levels between Ad-GFP-treated and Ad-DN-JNK-treated C57BL6 mice; after a 6-h fast, blood glucose levels in Ad-GFP-treated and Ad-DN-JNK-treated C57BL6 mice were 148 ± 9 mg/dl and 151 ± 8 mg/dl, respectively. Also there was no difference in the intraperitoneal glucose tolerance test (IPGTT) between Ad-GFP-treated and Ad-DN-JNK-treated C57BL6 mice. Next, to evaluate the effect on insulin sensitivity, we measured fasting serum insulin levels. After a 6-h fast, serum insulin levels in Ad-GFP-treated and Ad-DN-JNK-treated C57BL6 mice were almost same: 0.7 ± 0.4 ng/ml and 0.8 ± 0.4 ng/ml, respectively. Furthermore, to evaluate the effect of Ad-DN-JNK on insulin sensitivity in non-diabetic mice, we performed euglycemic hyperinsulinemic glucose clamp test in C57BL6 mice. In contrast to C57BLKsJ-db/db mice, there was no difference in glucose infusion rate (GIR) between Ad-GFP-treated and Ad-DN-JNK-treated C57BL6 mice (73.7 ± 3.2 versus 73.4 ± 4.7 mg/kg/min, n = 5). These results are consistent with the idea that Ad-DN-JNK suppresses the JNK pathway which is activated under diabetic conditions and thus leads to decrease of insulin resistance and amelioration of glucose tolerance.
Alteration of insulin action in the liver via the JNK pathway is associated with the phosphorylation status of insulin signaling molecules and expression of gluconeogenic enzymes.
It has been reported that serine phosphorylation of insulin receptor substrate-1 (IRS-1) inhibits insulin-stimulated tyrosine phosphorylation of IRS-1, leading to an increase in insulin resistance (14, 17) . To explore the molecular mechanisms involved in the alteration of insulin actions via the JNK pathway, we evaluated IRS-1 serine 307 phosphorylation in the liver of Ad-WT-JNK-treated C57BL6 mice. As shown in Fig. 3A , IRS-1 serine 307 phosphorylation was increased in
Ad-WT-JNK-treated mice compared to Ad-GFP-treated mice. We also found a decrease in IRS-1 tyrosine phosphorylation in Ad-WT-JNK-treated mice compared to Ad-GFP-treated mice.
Furthermore, a decrease in Akt serine 473 phosphorylation was observed in Ad-WT-JNK-treated C57BL6 mice compared to Ad-GFP-treated mice. Similarly, we examined the molecular mechanisms involved in the reduction of insulin resistance by DN-JNK overexpression in the liver. As shown in Therefore, an increase in IRS-1 serine phosphorylation may be closely associated with the development of insulin resistance induced by JNK overexpression.
Next, we examined the expression levels of the key gluconeogenic enzymes, phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase), both of which are known to be regulated by insulin signaling. As shown in Fig. 3B , expression levels of both enzymes, G6Pase and PEPCK, were significantly increased by Ad-WT-JNK treatment in C57BL6 mice. In contrast, expression levels of both enzymes were markedly decreased by Ad-DN-JNK treatment in C57BL/KsJ-db/db mice. These results indicate that suppression of the JNK pathway 12 enhances insulin signaling which leads to a decrease in gluconeogenesis and amelioration of glucose tolerance.
Suppression of the JNK pathway in the liver improves high-fat, high-sucrose diet-induced insulin resistance and glucose tolerance.
Since it is well known that a high-fat and high-sucrose diet induces insulin resistance, we fed C57BL6 mice a high-fat, high-sucrose diet and examined whether suppression of the JNK pathway has any effect on high-fat, high-sucrose diet-induced insulin resistance. There was no difference in body weight and food intake between the two groups (data not shown). As shown in Fig. 4A , nonfasting blood glucose gradually became lower 2-3 weeks after the challenge in the DN-JNK-treated mice.
Four weeks after starting the high-fat, high-sucrose diet, nonfasting blood glucose and insulin concentrations were significantly lower in Ad-DN-JNK-treated mice compared to Ad-GFP-treated mice (nonfasting blood glucose: 115 ± 12 versus 157 ± 7mg/dl, p< 0.05; insulin concentration: 8.2 ± 1.5 versus 10.0 ± 1.2 ng/ml) (Fig. 4B) . To further investigate this point, we performed the intraperitoneal glucose tolerance test (IPGTT). As shown in Fig. 4C , blood glucose levels in
Ad-DN-JNK-treated mice were significantly lower compared to Ad-GFP-treated mice. These results indicate that suppression of the JNK pathway in the liver improves insulin resistance and glucose tolerance induced by a high-fat, high-sucrose diet. Taken together, suppression of the JNK pathway in the liver improves insulin resistance and ameliorates glucose tolerance in two different diabetic animal models with insulin resistance: C57BL/KsJ-db/db diabetic mice (Fig. 2) and high-fat, high-sucrose diet-induced diabetic mice (Fig. 4) .
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DISCUSSION
In this study, we show that activation of the JNK pathway in the liver using WT-JNK adenovirus increases insulin resistance and, in contrast, suppression of the JNK pathway using DN-JNK adenovirus decreases insulin resistance and markedly improves glucose tolerance in two different diabetic animal models with insulin resistance. These results suggest that the JNK pathway could be a potential therapeutic target for diabetes (Fig. 5) . In addition, while it is well known that various insulin target tissues such as adipose tissue and muscle as well as the liver are involved in the progression of insulin resistance, in our study insulin resistance of the whole body in db/db mice was markedly improved by DN-JNK overexpression only in the liver, although there was no difference in glucose disappearance rate. These results suggest that JNK activation in the liver plays a pivotal role in causing insulin resistance and glucose tolerance in the whole body.
The JNK pathway is known to be activated by several factors such as oxidative stress, free fatty acids (FFAs), tumor necrosis factor-(TNF-), all of which are known to be increased under diabetic conditions. Under diabetic conditions, reactive oxygen species (ROS) (19) are produced in various tissues (20) (21) (22) (23) and are involved in the development of insulin resistance (24-26) as well as the progression of -cell deterioration (18, (27) (28) (29) (30) (31) (32) . FFAs and TNF-are also likely to be involved in the development of insulin resistance; levels of FFAs and TNF-are increased under obese diabetic conditions with insulin resistance, which leads to a further increase in insulin resistance. Thus, although not examined in our study, we assume that improvement of insulin resistance by the suppression of the JNK pathway was at least in part counterbalancing the deleterious effects of several factors such as oxidative stress, FFAs and TNF-.
Here we report the dramatic improvement of insulin resistance by suppression of the JNK pathway, indicating the novel important role of the JNK pathway in insulin resistance. So far, the importance of the Ikappa kinase (IKK) pathway in insulin resistance has been reported (34, 35); 14 salicylate which inhibits the IKK pathway improves insulin resistance in skeletal muscle and decreases blood glucose levels in type 2 diabetic patients. Our present data suggest that specific inhibitors of the JNK pathway for the liver are potential therapeutic agents for insulin resistance in diabetic patients (36).
In conclusion, activation of the JNK pathway as seen under diabetic conditions increases insulin resistance, and in contrast, suppression of the JNK pathway decreases insulin resistance and markedly improves glucose tolerance in diabetic animal models. After a 6-h fast, glucose was injected intraperitoneally at a dose of 2.0 g/kg body weight, and blood glucose levels were measured. *, p<0.05, n = 6. 
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